Silvant Capital Management LLC Makes New Investment in DexCom, Inc. $DXCM

Silvant Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 79,562 shares of the medical device company’s stock, valued at approximately $5,359,000.

Other large investors have also recently modified their holdings of the company. Reflection Asset Management acquired a new position in shares of DexCom during the fourth quarter worth $25,000. Ascentis Independent Advisors acquired a new stake in DexCom in the first quarter valued at $25,000. MCF Advisors LLC acquired a new stake in DexCom in the fourth quarter valued at $32,000. Wellington Grp LLC raised its position in DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC bought a new position in DexCom during the 4th quarter worth $36,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $90.22 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The firm has a market cap of $34.05 billion, a price-to-earnings ratio of 35.66, a PEG ratio of 1.52 and a beta of 1.41. The company’s fifty day simple moving average is $77.15 and its 200 day simple moving average is $70.79. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $91.96.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the business posted $0.48 EPS. The business’s revenue was up 13.1% compared to the same quarter last year. On average, analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at $7,075,708.50. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the sale, the director owned 48,852 shares of the company’s stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,035 shares of company stock worth $5,446,673 in the last quarter. 0.28% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on DXCM shares. Deutsche Bank Aktiengesellschaft initiated coverage on DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price on the stock. Truist Financial set a $93.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Citigroup restated a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Barclays reaffirmed an “underweight” rating and issued a $64.00 price objective (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Finally, Stifel Nicolaus set a $95.00 target price on DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.